Hemabate (Carboprost)

Hemabate is indicated for the management of postpartum hemorrhage and related uterine conditions where rapid uterine contraction is required.

• Treatment of postpartum hemorrhage caused by uterine atony.
• Control of bleeding after cesarean delivery when uterine tone is inadequate.
• Management of severe postpartum bleeding unresponsive to oxytocin.
• Adjunct therapy for uterine atony during surgical obstetric procedures.
• Emergency use for refractory uterine bleeding when other uterotonics have failed.
• Prevention of excessive uterine bleeding in high‑risk deliveries.

The safety profile of Hemabate includes both frequently observed and less common adverse reactions.

Common

• Abdominal or pelvic cramping.
• Diarrhea or loose stools.
• Nausea and occasional vomiting.
• Fever or chills.
• Headache or dizziness.
• Injection site pain or erythema.
• Transient tachycardia.
• Mild hypertension.

Serious

• Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty.
• Significant hypotension or cardiovascular collapse.
• Pulmonary edema or severe respiratory distress.
• Massive hemorrhage due to uterine rupture.
• Renal impairment.
• Seizures.
• Cardiac arrhythmias.

Before using Hemabate, healthcare providers should evaluate patient history and clinical status to minimize risks.

• Contraindicated in patients with known hypersensitivity to carboprost or other prostaglandin analogs.
• Use with caution in individuals with asthma or severe respiratory disease, as bronchospasm may occur.
• Avoid in patients with active cardiovascular disease, including hypertension or coronary artery disease.
• Assess renal and hepatic function prior to administration, especially in patients with impairment.
• Monitor for signs of uterine rupture or excessive uterine contraction during treatment.
• Use only under direct medical supervision; not intended for self‑administration.
• Consider alternative uterotonics if the patient is pregnant beyond the recommended gestational age for prostaglandin use.

Hemabate may interact with other medications, affecting efficacy or safety.

Avoid

• Concurrent use with other prostaglandin analogs (e.g., misoprostol) due to additive uterine effects.
• Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase risk of gastrointestinal bleeding.
• Simultaneous administration with anticoagulants or antiplatelet agents that may exacerbate bleeding.

Use with caution

• Oxytocin or other uterotonics: may require dose adjustment to prevent overstimulation.
• Beta‑agonist bronchodilators: monitor respiratory status in asthmatic patients.
• Antihypertensive agents: observe blood pressure changes due to possible vasoconstriction.
• Diuretics: watch for fluid balance alterations in patients with renal impairment.